Insititute for Clinical Pharmacodynamics: Presentations

BY CONFERENCE

ECCMID 2008, P553
Jones R, Ambrose P, Wikler M.
Definition of wildtype MIC distributions for targeted species for determination of optimal dosing for zabofloxacin, a novel fluoronaphthyridone

ECCMID 2008, O152
Rubino CM, Bhavnani SM, Forrest A, Okusanya OO, Lehoux D, Drusano GL, Rodvold KA, Craig WA, Parr Jr. TR, Ambrose PG
Use of pharmacokinetic-pharmacodynamic principles for decision support for short-course oritavancin dosing regimens for complicated skin and skin structure infections

ECCMID 2008, P1261
Ambrose P, Bhavnani S, Jones R, Wikler M.
Analyses supporting phase 2 clinical trial dose selection for zabofloxacin in community-acquired pneumonia

ECCMID 2006, P-1524
Lodise T.P., Ma L., Pypstra R., Kahn J., Drusano G.L., Noel G.L.
Pharmacodynamic Profiling of Ceftobiprole for the Treatment of Complicated Skin and Skin Structure Infections and Nosocomial Pneumonia

ECCMID 2006, P-1553
Sader H., Bhavnani S.M., Ambrose P.G., Jones R.
Re-evaluation of the role of broad-spectrum cephalosporins against staphylococci applying contemporary in vitro results and pharmacokinetic-pharmacodynamic principals

ECCMID 2006, O-361
Bhavnani S.M., Rubino C.M., Ambrose P.G., Korth-Bradley J., Speth J., Ellis-Grosse E.J., Drusano G.L.
Pharmacokinetic-pharmacodynamic analyses of efficacy using estimates of serum and effect site tigecycline exposures in patients with complicated intra-abdominal infections

ECCMID 2006, O-360
Rubino C.M., Ma L., Bhavnani S.M., Korth-Bradley J., Speth J., Ellis-Grosse E.J., Ambrose P.G., Drusano G.L.
Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation

ECCMID 2005, 100
Meagher A, Smith P, Forrest A, Odundele A, Ambrose PG.
Pharmacodynamic characterisation of LMB415 against Haemophilus influenzae in an in vitro hollow-fibre system.

ECCMID 2005, 103
Bhavnani SM, Drusano GL, Ambrose PG.
Impact of adverse drug events on resource consumption: amoxicillin-clavulanate vs gemifloxacin.

ECCMID 2005, 107
Lodise TP, Rhoney DH, Tam VH, Parker D, McKinnon PS, Drusano GL.
Pharmacodynamic profiling of cefepime in the cerebrospinal fluid of hospitalised patients through the use of population pharmacokinetic modelling and Monte Carlo simulation.

ECCMID 2005, 382
Meagher A, Ambrose PG, Passarell J, Cirincione BB, Babinchak T, Ellis-Grosse EJ.
A novel approach for evaluating the microbiological efficacy of tigecycline in patients with complicated skin and skin-structure infections.

ECCMID 2004, 256
Drusano GL.
Utility of the 750 mg dose of levofloxacin against Streptococcus pneumoniae as assessed by Monte Carlo simulation and expectation over a large MIC distribution.

ECCMID 2003, P1035
Bhavnani SM. Hammel P, Forrest A, Ambrose PG, Jones RN.
Relationships between susceptibility of Enterobacter spp. and hospital- and patient-specific variables.

ECCMID 2002, 1364
Drusano GL and Preston SL.
Utility of an 800-mg dose of telithromycin for CAP caused by extracellular pathogens: a preliminary assessment by pharmacodynamic modeling and Monte Carlo simulation.

ECCMID 2001
Drusano GL.
Strategies for maximising power, minimising resistance.

ECCMID 2000
Drusano GL, Preston SL, Hayden F, Treanor J, Qu R, Gisclon L, Fowler C.
Time to viral clearance after experimental influenza a infection is related to the baseline viral titer and the plasma area under the curve of RWJ-270201.